We use cookies to provide some features and experiences in QOSHE

More information  .  Close
Aa Aa Aa
- A +

Teva reaches $21m settlement with Rhode Island over opioid-related claims

18 2 16

Teva Pharmaceuticals, the US subsidiary of Israel’s generic drugmaker giant Teva Pharmaceutical Industries, will pay the US state of Rhode Island $21 million to settle its opioid-related claims against the company and provide doses of generic medicines that aid in opioid addiction and recovery, valued at $78.5 million.

According to the settlement agreement, the $21 million will be paid to Rhode Island over a period of 13 years, and doses of Narcan (naloxone hydrochloride nasal spray) and buprenorphine naloxone, an opioid medication in tablet form known by the brand name Suboxone, will be made available over 10 years, Teva said in a statement Monday.

The agreement is the latest in a number of recent opioid-related settlements between Teva and US states including Louisiana, California, and Texas, amid ongoing claims that Teva and other drugmakers like Johnson & Johnson, Endo International, and AbbVie’s Allergan engaged in misleading marketing of opioid drugs and downplayed the risks of addiction.

The state of Louisiana claimed that Teva and other pharmaceutical companies “engaged in fraudulent marketing regarding the risks and benefits of prescription opioids, which helped fuel Louisiana’s opioid epidemic.” Teva reached a $15 million settlement with the state in September.

In late December, a suburban New York jury ruled that Teva Pharmaceuticals contributed to the opioid crisis, in one of the verdicts so far among thousands of lawsuits nationwide over the........

© The Times of Israel

Get it on Google Play